This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Menquadfi, Menveo, Nimenrix
- Generic Name
- Meningococcal polysaccharide vaccine group W-135
- DrugBank Accession Number
- DB13887
- Background
Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
- Type
- Biotech
- Groups
- Approved, Experimental, Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Meningococcal polysaccharide antigen group W-135
- neisseria meningitidis group W-135 capsular polysaccharide antigen
- Neisseria meningitidis group W-135 polysaccharide antigen, A
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Invasive meningococcal infection caused by neisseria meningitidis serogroup w-135 •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET Meningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (4 mcg/0.5ml) Injection, solution Intramuscular SANOFİ PASTEUR AŞI TİC. A.Ş. 2012-11-07 Not applicable Turkey 
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET Meningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (4 mcg/0.5ml) Injection, solution Intramuscular SANOFİ PASTEUR AŞI TİC. A.Ş. 2020-08-14 Not applicable Turkey MENACTRA® Meningococcal polysaccharide vaccine group W-135 (4 mcg) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (48 mcg) + Meningococcal polysaccharide vaccine group C (4 mcg) + Meningococcal polysaccharide vaccine group C (4 mcg) + Meningococcal polysaccharide vaccine group Y (4 mcg) Solution Intramuscular SANOFI AVENTIS DE COLOMBIA S.A 2010-02-12 2018-08-29 Colombia 
MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET Meningococcal polysaccharide vaccine group W-135 (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (50 mcg/0.5ml) Injection, powder, for solution Subcutaneous PFİZER PFE İLAÇLARI A.Ş. 2020-08-14 2019-07-01 Turkey Menomune - A/c/y/w-135 Combined Meningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL) Injection; Kit Subcutaneous Sanofi Pasteur Inc. 1981-11-23 2017-09-10 US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9F8QQ6EER1
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- FDA label
- Download (83.9 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Papilloma Viral Infection 1 4 Completed Basic Science Meningitis / Meningococcal Disease / Septicemia 1 4 Completed Other Meningococcal Meningitis 1 4 Completed Prevention Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus 1 4 Completed Prevention Diphtheria / Meningitis / Meningococcal sepsis / Pertussis / Tetanus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular Solution Intramuscular Injection, powder, for solution Subcutaneous Injection; kit Subcutaneous Kit; powder, for solution Subcutaneous Powder, for solution Subcutaneous Powder Intramuscular Powder, for solution; solution Intramuscular Injection, powder, lyophilized, for solution Intramuscular Injection, powder, for solution Intramuscular Injection, powder, for solution Intramuscular 10 mcg/0.5ml Kit; powder, for solution Intramuscular Injection, powder, for solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at September 08, 2017 20:22 / Updated at June 12, 2020 16:53